ClinicalTrials.gg
CompletedNCT07616791INT-210-I101Updated Jun 1, 2026

A Phase I Study of INT-210 Capsules in Healthy Adult Subjects (INT-210-I101)

A Phase 1 interventional study of INT-210 Capsule and INT-210 Capsule in IBD (Inflammatory Bowel Disease), sponsored by Innatus Therapeutics (Shanghai) Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Innatus Therapeutics (Shanghai) Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2025, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.

Enrollment
33rd of 60
86 · median 97
Started
2025
with 25 others
Phase 1
13 of 114
6 open now
Registered
106th of 114
by date

Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 33rd largest by enrollment of the 60 interventional ones that give a count, is one of 26 that started in 2025, is one of 13 in phase 1, and was the 106th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Inflammatory Bowel Diseases with a site in China, or all of them as a file.
02

Study summary

A Phase Ⅰ, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability and Pharmacokinetics of INT-210 Capsules in Healthy Adult Voluteers.

Primary Objectives:

● To assess the safety and tolerability of single and multiple oral dose of INT-210 capsules in healthy adult voluteers,

Secondary Objectives:

  • To assess the pharmacokinetic(PK) profile of single and multiple oral doses of INT-210 capsules in healthy adult voluteers;
  • To assess the safety and tolerability of INT-210 capsulese administered under fasting and fed(high-fat-meal) conditions in healthy adult voluteers;
  • To assess the effect of food on the PK profile of a single oral dose of INT-210 capsules in healthy adult voluteers;
03

Conditions studied

  • IBD (Inflammatory Bowel Disease)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female healthy voluteers
  • Aged 18-45 years(inclusive),
  • In good general health with no evidence of active or chronic disease; and who agree to comply with the prescribed requirement during the trial and for 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Female who are pregnant or breastfeeding; or planing pregnancy, female of chidbearing potential not using adequate .
  • Pre-existing significant medical conditions(cardiac, hepatic, renal, gastrointestina, etc), abnormal lab results, active infection, or history of special conditions like long syndrome or hypocalcemia.
  • Positive screening for , /C or syphilis;
  • Recent subject in another clinical trial;
  • Recent major surgery, or significant blood loss.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose from 50 mg to 800 mg

    Single Ascending Dose

    Drug: INT-210 Capsule

  • Experimental
    Food Effect: 400mg

    Drug: INT-210 Capsule

  • Experimental
    Multiple Ascending Dose: 200 mg to 600mg

    BID

    Drug: INT-210 Capsule

  • Placebo comparator
    Placebo

    Placebo for SAD, MAD and Food Effect

    Drug: INT-210 Placebo

Interventions

  • DrugINT-210 Capsule

    400 mg INT-210; Oral administration

  • DrugINT-210 Capsule

    Escalating doses of 50, 100, 200, 400, 600, 800 mg of INT-210; Single dose administration; Oral administration

  • DrugINT-210 Capsule

    Escalating doses of 200, 400, 600 mg of INT-210; BID; Oral administration

  • DrugINT-210 Placebo

    INT-210 Placebo BID

06

What researchers measure

Primary outcomes

  1. The incidence of treatment-emergent adverse events

    Number of participants with treatment-related adverse events as assessed. The incidence of treatment-emergent adverse events will be measured using a combination of data collection methods, including tracking adverse events and assessing their onset or worsening relative to the initiation of treatment. The most recent version of the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms will be used to classify adverse events, including their relationship to the treatment and maximum severity.

    Time frame: From Day 1 through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

  2. Treatment-emergent potentially clinically- significant abnormalities in safety laboratory parameters-hematology

    Hemoglobin, Hematocrit, Erythrocytes, Mean corpuscular volume, Platelets, Leukocytes, Eosinophils, Basophils, Neutrophils, Lymphocytes, Monocytes

    Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

  3. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulation

    Activated partial thromboplastin time, Prothrombin time, International Normalized Ratio, Fibrinogen

    Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

  4. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum chemistry

    Glucose, Blood urea nitrogen, Creatinine, Sodium, Potassium, Calcium, Chloride, Magnesium, Bicarbonate, Phosphate, Bilirubin, total and direct, Alkaline phosphatase, Aspartate transaminase (=SGOT), Alanine transaminase (=SGPT), Gamma glutamyl transferase, Total protein, Albumin, Creatine kinase, Lactate dehydrogenase (LDH)

    Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

  5. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: urinalysis

    Specific gravity, PH, Glucose, Protein, Nitrite , Urobilinogen, Occult Blood, White blood cells, Ketones, Red blood cells

    Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

  6. Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)

    ECG assessment (QTcF) as determined by the Investigator/consulting board-certified cardiologist

    Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

  7. Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)

    Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

  8. Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)

    Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

  9. Treatment-emergent potentially clinically significant abnormalities in vital signs: respiration rate (BPM)

    Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

  10. Treatment-emergent potentially clinically significant abnormalities in vital signs: hemoglobin saturation (%)

    Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

  11. Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (℃)

    Time frame: From enrollment through the safety follow-up visit on either Day 8 (SAD) or Day 21 (MAD)

Secondary outcomes

  1. Pharmacokinetics parameter: Cmax of INT-210

    Maximum observed plasma concentration (ng/mL)

    Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11

  2. Pharmacokinetics parameter: Tmax of INT-210

    Time of maximum observed concentration (Tmax) of INT-210

    Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11

  3. Pharmacokinetics parameter: AUC (0-T) of INT-210

    Area Under the concentration-time curve from dosing to the time of the last measured concentration (AUC0-T) (h\*ng/L) of INT-210

    Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11

  4. Pharmacokinetics parameter: T1/2 of INT-210

    Half-life (T1/2) (hours) of INT-210

    Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11

  5. Pharmacokinetics parameter: CL/F of INT-210

    Apparent clearance (L/h) of INT-210

    Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11

  6. Pharmacokinetics parameter: Vz/F of INT-210

    Apparent volume of distribution (L) of INT-210

    Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11

  7. Pharmacokinetics parameter: AUCinf of INT-210

    Area under the curve from time 0 extrapolated to infinite time (AUCinf) (h\*ng/L) of INT-210

    Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11

Other outcomes

  1. Potential risk of QT/QTc interval prolongation of INT-210

    A correlation model will be constructed using drug concentrations and ECG parameters to analyze the concentration-QTc relationship, and the potential risk of QT/QTc interval prolongation will be assessed by establishing a "concentration-effect model".

    Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11

  2. Fraction excreted: Fraction of drug excreted unchanged in urine and Feces

    Fraction of dose excreted unchanged into urine and feces as a percentage (%)

    Time frame: SAD: From Day 1 to Day 4; MAD: From Day 1 to Day 13; Food Effect: From Day 1 to Day 11

07

Study locations

1 site
  • Beijing Municipality - Beijing Municipality - No. 101, Luyuan East Road, Tongzhou District, Beijing
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Jan 2026, 4 months.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 4 months is below that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
Jun 1, 2026
StartActual
Sep 4, 2025
Primary completionActual
Jan 6, 2026
CompletionActual
Jan 6, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07616791
Lead sponsor
Innatus Therapeutics (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Sep 4, 2025
Primary completion
Jan 6, 2026
Completion
Jan 6, 2026
Last update
Jun 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion